Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral (pyrotinib), Intravenous (nab-paclitaxel)
01
Overview
Pyrotinib + nab-paclitaxel is a combination therapy used primarily in the treatment of HER2-positive breast cancer, including both early and advanced/metastatic settings. Pyrotinib is an oral, irreversible pan-HER tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR/HER1), HER2, and HER4, thereby blocking downstream signaling pathways involved in tumor cell proliferation and survival. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is a microtubule inhibitor formulated with albumin nanoparticles to improve solubility and reduce solvent-related toxicities compared to conventional paclitaxel. The combination has demonstrated promising efficacy and acceptable safety profiles in clinical trials for patients with HER2-positive breast cancer[2][3][7].
- Brand names
- Abraxane (for nab-paclitaxel)Irene (for pyrotinib, in China)
- Other names
- albumin-bound paclitaxel (for nab-paclitaxel)
02
Targets
TUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on pyrotinib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + nab-paclitaxel.